Reduced stratum corneum acylceramides in autosomal recessive congenital ichthyosis with a NIPAL4 mutation

J Dermatol Sci. 2020 Jan;97(1):50-56. doi: 10.1016/j.jdermsci.2019.12.001. Epub 2019 Dec 4.

Abstract

Background: NIPAL4, encoding the NIPA-like domain containing 4 protein (NIPAL4), is one of the causative genes of autosomal recessive congenital ichthyosis (ARCI). The physiological role of NIPAL4 and the pathogenetic mechanisms of ARCI caused by NIPAL4 mutations remain unclear.

Objective: To clarify the changes of ceramide components in the lesional stratum corneum (SC) and the gene expression profile in the lesional skin of an ARCI patient with a novel frameshift mutation in NIPAL4.

Methods: We performed ultrastructural and immunohistochemical analyses of the skin. We used RNA sequencing to determine the mRNA expression in the skin of the patient and healthy individuals. We investigated ceramide components using tape stripped SC samples from the patient.

Results: mRNA expression profiling in the patient's skin showed significant upregulation of IL-17/TNFα-related genes (IL17C, IL36A, IL36G, S100A7A, S100A9) and psoriasis hallmark genes (VNN3, LCE3D, PLA2G4D), and significant downregulation of lipid-associated genes (GAL, HAO2, FABP7). Ceramide analysis in the patient's SC revealed amounts of CER[NS] with carbon chain-length (C) 32-52 were increased, while amounts of most acylceramide with C66:2 - C72:2 were reduced relatively to those in healthy individuals. After the retinoid treatment, CER[NS] with carbon chains C46-54, CER[EOH] and CER[EOP] increased.

Conclusion: IL-17C and IL-36 family cytokines might be involved in the pathogenetic process of ARCI with NIPAL4 mutations. Reduced amounts of the acylceramides in the SC are associated with the skin phenotype due to NIPAL4 mutations. Efficacy of the oral retinoid treatment might be due to restored amounts of CER[EOH] and CER[EOP] in the SC.

Keywords: Acylceramide; Autosomal recessive congenital ichthyosis; Ceramide; NIPAL4; Skin barrier; Stratum corneum.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Ceramides / analysis*
  • DNA Mutational Analysis
  • Epidermis / chemistry*
  • Epidermis / drug effects
  • Epidermis / pathology
  • Etretinate / administration & dosage*
  • Frameshift Mutation
  • Homozygote
  • Humans
  • Ichthyosis / drug therapy
  • Ichthyosis / genetics
  • Ichthyosis / pathology*
  • Male
  • Middle Aged
  • Receptors, Cell Surface / genetics*
  • Treatment Outcome

Substances

  • Ceramides
  • NIPAL4 protein, human
  • Receptors, Cell Surface
  • Etretinate

Supplementary concepts

  • Ichthyosis, Congenital, Autosomal Recessive, Ichthyin-Related